Morphine (Chlorhydrate) Renaudin (Morphine Hydrochloride)

Morphine, the active ingredient in Morphine (Chlorhydrate) Renaudin, is an opioid analgesic presented as a sterile injectable solution for epidural, intrathecal, intravenous use. It treats severe acute pain, postoperative pain, and cancer‑related pain in adult patients requiring potent analgesia.

GNH USA supplies Morphine (Chlorhydrate) Renaudin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Morphine is an opioid analgesic used for conditions that involve intense nociceptive or neuropathic pain.

Severe acute pain: provides rapid, strong analgesia for sudden, intense pain episodes. Postoperative pain: reduces pain and discomfort following surgical procedures. Cancer‑related pain: manages persistent, moderate‑to‑severe pain in oncology patients.

Morphine may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common after administration. - Constipation: reduced gastrointestinal motility. - Drowsiness or sedation: central nervous system depression. - Pruritus: itching, often at the injection site. - Miosis: pinpoint pupils. - Urinary retention: difficulty emptying the bladder.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing drive, potentially fatal. - Hypotension: significant drop in blood pressure. - Severe allergic reaction: rash, bronchospasm, anaphylaxis. - Dependence or addiction: risk of misuse with prolonged exposure. - Neurotoxicity: rare cases of seizures or delirium. - Cardiac arrhythmias: abnormal heart rhythms in susceptible patients.

Morphine requires careful monitoring and adherence to safety guidelines.

Dose titration: adjust dose gradually based on patient response and tolerance. Respiratory monitoring: observe for signs of depression, especially after initial dosing. Renal or hepatic impairment: consider reduced dosing or increased monitoring. Concomitant CNS depressants: avoid or use with caution when combined with benzodiazepines or alcohol. Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Morphine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other opioids: additive respiratory depression and sedation. - CNS depressants (e.g., benzodiazepines, barbiturates): profound sedation and respiratory compromise. - MAO inhibitors: risk of severe hypertension or serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): increased morphine plasma levels. - QT‑prolonging agents: potential for cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduced analgesic effect. - Anticholinergics: may worsen constipation. - Diuretics: can enhance hypotensive effects. - Antidepressants (SSRIs, SNRIs): possible serotonin syndrome when combined with high opioid doses. - NSAIDs: increased risk of gastrointestinal bleeding.